IDSA has updated our site with the term “mpox” to reduce stigma and other issues associated with prior terminology. This change is aligned with the Nov. 28, 2022, World Health Organization decision. Some webpages and materials created prior to this date, or linked to on other sites, may still reflect the old name.
Mpox is a rare disease caused by infection with a virus. Despite being originally named “monkeypox,” the source of the disease remains unknown. The first human case of mpox was recorded in 1970, in what is now the Democratic Republic of Congo.
Human-to-human transmission occurs primarily through direct contact with infected lesions or fluids or contact with contaminated materials like clothing or bedding. It also can be spread by respiratory droplets during prolonged face-to-face contact. Mpox has an average incubation period of 6 to 13 days, with a range of 5 to 21 days.
There are two subtypes of virus that cause mpox: clade I and clade II. Clade I causes more severe illness and deaths. Clade II, which causes less severe infections, is the type that caused a global outbreak of mpox in 2022-2023. Although a majority of cases in this outbreak occurred among gay and bisexual men, anyone can be affected by mpox regardless of sexual orientation. While evidence to date has not identified a new mechanism of infection unique to sexual transmission, mpox can be transmitted through prolonged physical contact, including intimate sexual contact. Case data by state and by age, gender, race/ethnicity and symptoms are available from the Centers for Disease Control and Prevention.
Useful Information and Resources
For the Public
For Clinicians
-
Centers for Disease Control and Prevention
- Notes from the Field: Clade II Mpox Surveillance Update — United States, October 2023–April 2024 (CDC, MMWR, May 23, 2024)
- U.S. Preparedness and Response to Increasing Clade I Mpox Cases in the Democratic Republic of the Congo — United States, 2024 (CDC, MMWR, May 16, 2024)
- Mpox Caused by Human-to-Human Transmission of Monkeypox Virus With Geographic Spread in the Democratic Republic of the Congo (CDC HAN Advisory, Dec. 7, 2023)
- The CDC Domestic Mpox Response — United States, 2022–2023 (CDC, MMWR, May 19, 2023)
-
Potential Risk for New Mpox Cases (CDC HAN Update, May 15, 2023)
-
IDSA/HIVMA
-
Vaccination
- Monkeypox Virus Infections After 2 Preexposure Doses of Jynneos Vaccine — United States, May 2022–May 2024 (CDC, MMWR, May 23, 2024)
- Estimated Effectiveness of Jynneos Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study — United States, Aug. 19, 2022–March 31, 2023 (CDC, MMWR, May 19, 2023)
- Effectiveness of Jynneos Vaccine Against Diagnosed Mpox Infection — New York, 2022 (CDC, MMWR, May 19, 2023)
- CDC Considerations for Mpox Vaccination
- HHS Mpox Vaccine Distribution by Jurisdiction
- Building Healthy Online Communities Vaccine Locator
-
Treatment
- National STD Curriculum Mpox Clinical Guide
- A5418 Clinical Trial Study of Tecovirimat for Human Monkeypox Virus (STOMP)
- CDC Clinical Considerations for Pain Management
- CDC Guidance for Tecovirimat Use Under Expanded Access Investigational New Drug Protocol
- CDC Obtaining and Using TPOXX (Tecovirimat) for Treatment of Mpox
- CDC Dear Colleague Letter on Pain Control
- Epic SmartText Available for Tecovirimat (TPOXX) Form A (Patient Intake Form) and Form B (Clinical Outcome Form): Mass General Brigham has posted to the Epic UserWeb for use by others an Epic SmartText to facilitate completion of Form A (Patient Intake Form) of the Expanded Access - New Investigational Drug protocol required for tecovirimat (TPOXX).
-
Department of Health and Human Services/National Institutes of Health Guidelines
-
Key Populations
- People With HIV, Children and Adolescents and People Who Are Pregnant or Breastfeeding (CDC HAN Update, July 30, 2022)
- CDC Clinical Considerations for Treatment and Prophylaxis of Mpox Infection in People With HIV
- CDC Clinical Considerations for Mpox in Children and Adolescents
- CDC Clinical Considerations for Mpox in People Who Are Pregnant or Breastfeeding
-
Infection Prevention & Control
-
Epidemiology
Public Policy, Advocacy and Action
- IDSA and HIVMA Letter to White House Office of Science and Technology Policy on Research Priorities – August 1, 2022
- HHS Monkeypox Letter – July 22, 2022 sent by IDSA with 40 stakeholder groups signing
- MPV Federal Funding Letter to Congress – July 19, 2022
- IDSA/HIVMA Statement: Stigma Has No Place in Public Health – May 26, 2022